Randomized Controlled Trials in Hereditary Cancer Syndromes

Chethan Ramamurthy; Yana Chertock; Michael J. Hall

doi:10.1016/j.soc.2017.05.011

Randomized Controlled Trials in Hereditary Cancer Syndromes

Chethan Ramamurthy
, Yana Chertock
, Michael J. Hall

Fox Chase Cancer Center

Research output: Contribution to journal › Review article › peer-review

Abstract

Conducting randomized controlled trials (RCTs) in patients with germline mutations in genes that predispose to adult-onset cancer is hampered by the rarity of these mutations, barriers to their identification, and challenges inherent to randomizing high-risk individuals as part of a clinical trial. Most of the clinically relevant RCTs have been conducted in 3 syndromes in only some of the high-risk genes for which clinical testing is currently available. This article reviews the surgical, screening, and chemoprevention RCTs in each of the syndromes in clinically relevant studies conducted in the past 10 years.

Original language	English
Pages (from-to)	729-750
Number of pages	22
Journal	Surgical Oncology Clinics of North America
Volume	26
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2017.05.011
State	Published - Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Clinical trials
FAP
Germline mutations
HBOC
HNPCC
Hereditary cancer syndromes
Lynch

Access to Document

10.1016/j.soc.2017.05.011

Cite this

@article{c706a44baab74ed885a160bfc4ae87a0,

title = "Randomized Controlled Trials in Hereditary Cancer Syndromes",

abstract = "Conducting randomized controlled trials (RCTs) in patients with germline mutations in genes that predispose to adult-onset cancer is hampered by the rarity of these mutations, barriers to their identification, and challenges inherent to randomizing high-risk individuals as part of a clinical trial. Most of the clinically relevant RCTs have been conducted in 3 syndromes in only some of the high-risk genes for which clinical testing is currently available. This article reviews the surgical, screening, and chemoprevention RCTs in each of the syndromes in clinically relevant studies conducted in the past 10 years.",

keywords = "Clinical trials, FAP, Germline mutations, HBOC, HNPCC, Hereditary cancer syndromes, Lynch",

author = "Chethan Ramamurthy and Yana Chertock and Hall, \{Michael J.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.soc.2017.05.011",

language = "English",

volume = "26",

pages = "729--750",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Randomized Controlled Trials in Hereditary Cancer Syndromes

AU - Ramamurthy, Chethan

AU - Chertock, Yana

AU - Hall, Michael J.

PY - 2017/10

Y1 - 2017/10

N2 - Conducting randomized controlled trials (RCTs) in patients with germline mutations in genes that predispose to adult-onset cancer is hampered by the rarity of these mutations, barriers to their identification, and challenges inherent to randomizing high-risk individuals as part of a clinical trial. Most of the clinically relevant RCTs have been conducted in 3 syndromes in only some of the high-risk genes for which clinical testing is currently available. This article reviews the surgical, screening, and chemoprevention RCTs in each of the syndromes in clinically relevant studies conducted in the past 10 years.

AB - Conducting randomized controlled trials (RCTs) in patients with germline mutations in genes that predispose to adult-onset cancer is hampered by the rarity of these mutations, barriers to their identification, and challenges inherent to randomizing high-risk individuals as part of a clinical trial. Most of the clinically relevant RCTs have been conducted in 3 syndromes in only some of the high-risk genes for which clinical testing is currently available. This article reviews the surgical, screening, and chemoprevention RCTs in each of the syndromes in clinically relevant studies conducted in the past 10 years.

KW - Clinical trials

KW - FAP

KW - Germline mutations

KW - HBOC

KW - HNPCC

KW - Hereditary cancer syndromes

KW - Lynch

UR - https://www.scopus.com/pages/publications/85027587745

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000412969600014&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.soc.2017.05.011

DO - 10.1016/j.soc.2017.05.011

M3 - Review article

C2 - 28923228

SN - 1055-3207

VL - 26

SP - 729

EP - 750

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

Randomized Controlled Trials in Hereditary Cancer Syndromes

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this